Ipilimumab-induced Lung Toxicity: Observational Study

CompletedOBSERVATIONAL
Enrollment

71

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2016

Conditions
Metastatic Melanoma
Interventions
OTHER

Pulmonary Function

Spirometry and DLCO were measured according to performance standards based on the statements from the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Values of DLCO were adjusted for the patient's current hemoglobin value, and the patients were asked to withhold cigarette smoking at least four hours before pulmonary function testing. Lung volumes and DLCO were measured with a commercial ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany)

Trial Locations (1)

8091

Department of Pulmonology, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT02755233 - Ipilimumab-induced Lung Toxicity: Observational Study | Biotech Hunter | Biotech Hunter